Statistical Misinterpretations and Clinical Practice Guidelines: any examples?

In this important paper on the interpretation of statistics in medicine, the authors write:

Blockquote
Misinterpretation and abuse of statistical tests, confidence intervals, and statistical power have been decried for decades, yet remain rampant. A key problem is that there are no interpretations of these concepts that are at once simple, intuitive, correct, and foolproof. Instead, correct use and interpretation of these statistics requires an attention to detail which seems to tax the patience of working scientists. This high cognitive demand has led to an epidemic of shortcut definitions and interpretations that are simply wrong, sometimes disastrously so—and yet these misinterpretations dominate much of the scientific literature.

I was curious if anyone had examples of guidelines that:

  1. commit one or more of the errors in described in the paper
  2. have become entrenched in institutional practice due to acceptance by regulatory authorities.

The closest threads that have approached the topic:

Addendum A quick search brought up this article by @Stephen, (inspired by @pmbrown just below) which is a good example of what I’m looking for:

2 Likes

maybe fda’s two trials rule and senn’s comments on that. Although i dont recall where this appears in fda material / edit: probably also critical response to recent ema guideline on subgroup analyses: Commentary on: Subgroup analysis and interpretation for phase 3 confirmatory trials: White Paper of the EFSPI/PSI working group on subgroup analysis by Dane, Spencer, Rosenkranz, Lipkovich, and Parke

1 Like

Several of these examples seem to have more to do with reification errors related to (but perhaps not quite the same as?) those discussed by @Sander [1], rather than with mere misinterpretations of statistical technicalities. That is, the problem is not merely technical, but “cognitive” or (I would rather say) “epistemological.” For example, apart from the utter lack of scholarship on FDA’s part which seems to be @Stephen’s main complaint in the linked post, he also is troubled by how artifacts emerging from a statistical analysis are presumed ipso facto to amount to real things (e.g., responders) that exist in the real world. A lot of @llynn’s concerns fall into the same category: artificial thresholds become reified (e.g., SIRS, OSA) as if they were per se the subject of investigation, rather than mere phenomena of the ding an sich. Likewise, the whole surrogate endpoints business is at least complicated by our predilection toward reifying frequently-used terms such as ‘progression-free survival’.

It seems to me that such cognitive/epistemological errors are far more insidious than technical errors in p-value interpretation, and much more capable of insinuating themselves into CPGs.

  1. Greenland S. Invited Commentary: The Need for Cognitive Science in Methodology. Am J Epidemiol. Published online 2017:1-7. doi:10.1093/aje/kwx259
3 Likes

Blockquote
It seems to me that such cognitive/epistemological errors are far more insidious than technical errors in p-value interpretation, and much more capable of insinuating themselves into CPGs.

Good point. This brings up 2 more questions:

  1. What does the clinician do when someone in authority makes policy decisions based upon things they “know” that really aren’t so?

  2. In the U.S., Federal regulators have made it clear that they intend to shift financial risk to providers of health services through policies like value based healthcare.

How can health service providers make defensible decisions when communities of clinicians and/or regulators are misled by these epistemological errors?

2 Likes

Have you been able to contact the authors of the paper to ask them for examples?
As a non-clinician reading clinical guidelines I’m quite astounded by how they can be put together. I’m not convinced that there is rigorous evaluation of the methodology and interpretation of the studies that inform guidelines.
In 2020 European Society of Cardiology made some changes to the guidelines for assessing patients in the Emergency Room with possible acute coronary syndrome. Those changes have come under some heavy criticism (Giannitsis E, et al. Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clin Res Cardiol. 2021 Available from: http://link.springer.com/10.1007/s00392-021-01821-2). I don’t think it is exactly what you are after [misinterpretations], but it does imply guideline changes were based on inadequate evidence.

2 Likes

“It seems to me that such cognitive/epistemological errors are far more insidious than technical errors in p-value interpretation, and much more capable of insinuating themselves into CPGs.”

This @davidcnorrismd post changed my understanding of “Threshold Science” which I have studied for over a decade.

I have long considered Threshold Science (The use of guessed threshold sets as gold standards or endpoints for RCT) a type of “pathological science”, after Langmuir, (wherein the “pathology” of the science is induced by an early undetected technical error in methodology.) Yet it never quite fit. Kuhn’s teachings also failed as the behavior he describes applies to both good science and pathological science.

I see now that Threshold Science comprises a different type of pathological science induced by a fundamental cognitive error rather than a technical error
The distinction between Langmuir’s Type I pathological science (fundamental methodological error) and Type II (fundamental cognitive error) is very important. Trusting, dutiful and particulatly the best trained in the discipline will be not be able to detect the error of Type II Pathological Science whereas they may be be able to detect the error of Type I.

Type II pathological science is probagated by text and mentorship. Indeed, since all in the disipline are unknowingly faithful to the pathologic teaching, its practice is mandated to receive funding and to publish in the top journals.

An entire scientific discipline (eg sleep apnea science), may be based on Type II pathological science. They may recognize that the science is not working but they will be complely confused as they cannot understand why.

Here is another good example, mentioned in another data methods thread:

Blockquote
We find that in all cases the provision of HHC increased the probability of readmission of the treated patients. This casts doubt on the appropriateness of the 30-day readmission rate as an indicator of hospital performance and a criterion for hospital reimbursement, as it is currently used for Medicare patients.

Alecos Papadopoulos & Roland B. Stark (2021) Does Home Health Care Increase the Probability of 30-Day Hospital Readmissions? Interpreting Coefficient Sign Reversals, or Their Absence, in Binary Logistic Regression Analysis, The American Statistician, 75:2, 173-184, DOI: 10.1080/00031305.2019.1704873 link

It is a shame this paper is paywalled, but here is a brief blog post by one of the authors:

1 Like

Another good example found on Dr. Harrell’s blog – not sure how I missed it,

2 Likes